Destiny Pharma consultant Professor Dale Gerding updates on recurrent C. difficile infections work - Video

Destiny Pharma's key consultant and member of the Scientific Advisory Board Professor Dale Gerding provides an update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections.

The NTCD-M3 programme targets the prevention of the recurrence of clostridium difficile infection and has been developed through the world leading research of Professor Dale Gerding.